Fujifilm (OTCMKTS:FUJIY) Shares Pass Above 200-Day Moving Average - Here's What Happened

Key Points

• Fujifilm's stock recently surpassed its 200-day moving average, trading as high as $12.36, with a last traded price of $12.35.
• Wall Street Zen downgraded Fujifilm from a "buy" rating to a "hold" rating as of May 23rd.
• The company reported a quarterly earnings per share (EPS) of $0.15, in line with analysts' expectations, on revenue of $5.08 billion.

Fujifilm Holdings Corp. (OTCMKTS:FUJIY - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $10.75 and traded as high as $12.36. Fujifilm shares last traded at $12.35, with a volume of 82,754 shares changing hands.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered shares of Fujifilm from a "buy" rating to a "hold" rating in a report on Friday, May 23rd.

Fujifilm Price Performance

The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.92 and a current ratio of 1.48. The stock has a market cap of $29.95 billion, a PE ratio of 10.85, a PEG ratio of 2.37 and a beta of 0.67. The stock's 50-day moving average is $11.48 and its two-hundred day moving average is $10.76.

Fujifilm (OTCMKTS:FUJIY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The technology company reported $0.15 earnings per share for the quarter, hitting analysts' consensus estimates of $0.15. Fujifilm had a net margin of 7.93% and a return on equity of 7.60%. The firm had revenue of $5.08 billion during the quarter, compared to analysts' expectations of $760.41 billion. On average, equities analysts predict that Fujifilm Holdings Corp. will post 0.66 earnings per share for the current year.

Fujifilm Company Profile

FUJIFILM Holdings Corporation develops, manufactures, sells, and services imaging, healthcare, materials, and business innovation solutions worldwide. The company's Healthcare segment provides products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment.